Voltar
Carta Acesso aberto Revisado por pares
BIBTEX RIS

Trametinib inhibits RAS -mutant MLL -rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo

2018; Ferrata Storti Foundation; Volume: 103; Issue: 4 Linguagem: Inglês

10.3324/haematol.2017.174060

ISSN

1592-8721

Autores

Mark Kerstjens, Sandra S. Pinhanços, Patricia Garrido Castro, Pauline Schneider, Priscilla Wander, Rob Pieters, Ronald W. Stam,

Tópico(s)

Chronic Myeloid Leukemia Treatments

Resumo

The majority (approx. 80%) of infant acute lymphoblastic leukemia (ALL) cases are characterized by chromosomal rearrangements involving the Mixed Lineage Leukemia ( MLL , or KMT2A ) gene, which confer a poor prognosis: chances of event-free survival are 30–40% at best.[1][1] We and others showed

Referência(s)